申请人:Glaxo Group Limited
公开号:US07674789B2
公开(公告)日:2010-03-09
The present invention is directed to compounds of formula (I), (Ia),(Ic) and (Id), compositions, and uses thereof as an inhibitor of the p38 kinase, and
wherein, inter alia
R1 is C(Z)N(R10′)(CR10R20)vRb, C(Z)O(CR10R20)vRb, N(R10′)C(Z)(CR10R20)vRb; N(R10′)C(Z)N(R10′)(CR10R20)vRb; or N(R10′)OC(Z)(CR10R20)vRb;
R3 is C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroarylC1-10 alkyl, or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted;
X is R2, OR2′, S(O)mR2′, (CH2)n′N(R10′)S(O)mR2′, (CH2)n′N(R10′)C(O)R2′, (CH2)n′NR4R14, (CH2)n′N(R2 ′)(R2″), or N(R10′)—Rh—NH—C(═N—CN)NRqRq′; and
R2 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic, or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or a pharmaceutically acceptable salt thereof.
本发明涉及化合物(I)、(Ia)、(Ic)和(Id)、组合物及其用途,作为p38激酶的抑制剂,其中,R1是C(Z)N(R10′)(CR10R20)vRb、C(Z)O(CR10R20)vRb、N(R10′)C(Z)(CR10R20)vRb;N(R10′)C(Z)N(R10′)(CR10R20)vRb;或N(R10′)OC(Z)(CR10R20)vRb;R3是C1-10烷基、C3-7环烷基、C3-7环烷基C1-10烷基、芳基、芳基C1-10烷基、杂芳基C1-10烷基或杂环基C1-10烷基基团,其中这些基团可以选择性地被取代;X是R2、OR2′、S(O)mR2′、(CH2)n′N(R10′)S(O)mR2′、(CH2)n′N(R10′)C(O)R2′、(CH2)n′NR4R14、(CH2)n′N(R2′)(R2″)或N(R10′)—Rh—NH—C(═N—CN)NRqRq′;R2是氢、C1-10烷基、C3-7环烷基、C3-7环烷基烷基、芳基、芳基C1-10烷基、杂芳基、杂芳基C1-10烷基、杂环基或杂环基C1-10烷基基团,其中这些基团(不包括氢)可以选择性地被取代;或其药学上可接受的盐。